Immunome (IMNM) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Septerna (SEPN) has outperformed Immunome (IMNM) over the past year, gaining 51.1% versus a loss of 15.3%. Immunome is the larger company by market cap ($1.85 billion vs $1.84 billion), about 1.0 times the size, while Septerna is growing revenue faster (+4174.5% vs -23.2%). Septerna converts more of its revenue into profit, with a net margin of -106.4% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | SEPN |
|---|---|---|
| Share price | $15.69 | $38.61 |
| Market cap | $1.85B | $1.84B |
| 1-day change | -5.54% | -1.51% |
| YTD return | -26.96% | +38.49% |
| 1-year return | -15.33% | +51.06% |
| 5-year return | -7.54% | — |
| EPS (TTM) | $-2.63 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $45.95M |
| Revenue growth (YoY) | -23.23% | +4174.51% |
| Net income (latest FY) | $-212.39M | $-48.88M |
| Operating margin | -3228.83% | -148.63% |
| Net margin | -3059.99% | -106.37% |
| 52-week high | $30.06 | $53.34 |
| 52-week low | $15.55 | $22.78 |
| Distance from 52-week high | -47.80% | -27.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.90% | +53.38% |
| Average volume | 1.36M | 383.96K |
| Shares outstanding | 118.07M | 47.55M |
| Employees | 267 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed IMNM by 66.4 percentage points over the past year.
- Septerna is more profitable, keeping -106.4 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
IMNM vs SEPN FAQ
Which is bigger, Immunome or Septerna?
Immunome (IMNM) is larger, with a market capitalization of $1.85B compared with $1.84B for Septerna (SEPN).
Which stock has performed better over the past year, IMNM or SEPN?
SEPN returned +51.06% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.